Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 101–200 of 982
Metabolic reprogramming and its clinical implication for liver cancer
Yang, F., Hilakivi-Clarke, L. A., Shaha, A., Wang, Y., Wang, X., Deng, Y., Lai, J., & Kang, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000005 · Cited by 199
Sarcoma Epidemiology and Etiology: Potential Environmental and Genetic Factors
Lahat, G., Lazar, A., & Lev, D. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.03.006 · Cited by 194
“Most HLRCC tumors overexpress hypoxia-inducible factor (HIF) 1a and its target genes, such as VEGF and BNIP3, and have increased vascularity in comparison to their sporadic counterparts [111,112].”
BackgroundRecurrent epimutation of SDHC in gastrointestinal stromal tumors
Killian, J. K., Miettinen, M., Walker, R. L., Wang, Y., Zhu, Y. J., Waterfall, J. J., Noyes, N., Retnakumar, P., Yang, Z., Smith, W. I., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009961 · Cited by 193
Role of mitochondrial alterations in human cancer progression and cancer immunity
Wang, S.-F., Tseng, L.-M., & Lee, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00956-w · Cited by 192
You, Y.-H., Quach, T., Saito, R., Pham, J., & Sharma, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030302 · Cited by 192
Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia
Qutub, A. A., & Popel, A. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00060-08 · Cited by 191
Janke, R., Dodson, A. E., & Rine, J. (2015) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125544 · Cited by 191
“As a result of SDH inactivity, these tumors accumulate up to millimolar concentrations of succinate, a product of the reactions catalyzed by FeII- and α-ketoglutarate–dependent dioxygenases (Pollard et al. 2005).”
BackgroundThe emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
“Fumarate hydratase-deficient cells and tumors have been shown to accumulate fumarate to very high levels with multiple consequences including the activation of oncogenic pathways (Isaacs et al., 2005; Pollard et al., 2005).”
BackgroundSelf-citationOxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect
Chen, Y., Cairns, R., Papandreou, I., Koong, A., & Denko, N. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007033 · Cited by 187
“The mechanism by which they can suppress tumorgenicity has yet to be fully determined, but it has been shown that these mutations cause a buildup of TCA intermediates that can lead to stabilization of the HIF1 transcription factor [21].”
BackgroundRedox regulation of the hypoxia-inducible factor
Pouysségur, J., & Mechta-Grigoriou, F. (2006) · Biological Chemistry · doi:10.1515/bc.2006.167 · Cited by 186
“In addition to 2- oxoacids, accumulation of TCA cycle intermediates (such as succinate) as a result of mutation in the gene encoding succinate deshydrogenase inhibits PHD activity and stabilizes HIF under normoxia through a feedback inhibition mechanism (Pollard et al., 2005; Selak et al., 2005).”
BackgroundCommandeur, A. E., Styer, A. K., & Teixeira, J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv030 · Cited by 186
Aspuria, P.-J. P., Lunt, S. Y., Väremo, L., Vergnes, L., Gozo, M., Beach, J. A., Salumbides, B., Reue, K., Wiedemeyer, W. R., Nielsen, J., et al. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-21 · Cited by 185
Hong, S.-B., Oh, H., Valera, V. A., Baba, M., Schmidt, L. S., & Linehan, W. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015793 · Cited by 183
“and angiogenesis [3,4].”
Regulation of human metabolism by hypoxia-inducible factor
Formenti, F., Constantin-Teodosiu, D., Emmanuel, Y., Cheeseman, J., Dorrington, K. L., Edwards, L. M., Humphreys, S. M., Lappin, T. R. J., McMullin, M. F., McNamara, C. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002339107 · Cited by 182
“Metabolic changes also could affect 2-oxoglutarate concentrations, and these concentrations in turn affect the level of HIF (52, 53).”
BackgroundHYPOXIA‐INDUCED ERYTHROPOIETIN PRODUCTION: A PARADIGM FOR OXYGEN‐REGULATED GENE EXPRESSION
Stockmann, C., & Fandrey, J. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04474.x · Cited by 153
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
“8 pheochromocytoma and papillary renal cell carcinoma, indicating that these enzymes function as tumor suppressors[45].”
Lee, S., & Griffiths, J. R. (2020) · Cancers · doi:10.3390/cancers12061616 · Cited by 179
Self-citationOncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 178
“Mutations in SDH are found in familial paraganglioma and pheochromocytoma [14 – 17, 24 , 25 One of the most striking features of SDH-de fi cient cells is the accumulation of succinate [31], a metabolite implicated in tumorigenesis and, for this reasons, recently de fi ned an oncometa-bolite [32].”
BackgroundPollard, P. J., Spencer-Dene, B., Shukla, D., Howarth, K., Nye, E., El-Bahrawy, M., Deheragoda, M., Joannou, M., McDonald, S., Martin, A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.005 · Cited by 178
Self-citationCurrent and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Jimenez, C., Rohren, E., Habra, M. A., Rich, T., Jimenez, P., Ayala-Ramirez, M., & Baudin, E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0320-x · Cited by 178
Rohan, S. M., Xiao, Y., Liang, Y., Dudas, M. E., Al-Ahmadie, H. A., Fine, S. W., Gopalan, A., Reuter, V. E., Rosenblum, M. K., Russo, P., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.80 · Cited by 176
Brière, J.-J., Favier, J., Bénit, P., Ghouzzi, V. E., Lorenzato, A., Rabier, D., Di Renzo, M. F., Gimenez-Roqueplo, A.-P., & Rustin, P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi359 · Cited by 152
“We found a huge succinate accumulation in SDHA-mutant cells as previously detected in PG samples (10,16).”
BackgroundInfluentialSelf-citationOncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
Hardie, D. G. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390001 · Cited by 172
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanova, I., Yang, C., Zhuang, Z., & Pacak, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 172
“(134,139) found relatively more common HIF-2α overexpression in VHL PHEOs and PGLs, whereas in SDH tumors nuclear HIF-1α staining was more prominent.”
BackgroundInfluentialAlpha-Ketoglutarate dietary supplementation to improve health in humans
Gyanwali, B., Lim, Z. X., Soh, J., Lim, C., Guan, S. P., Goh, J., Maier, A. B., & Kennedy, B. K. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.11.003 · Cited by 173
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 170
“Dysfunction in these two enzymes has been linked to the development of various cancers [84].”
BackgroundDNA demethylation pathways: Additional players and regulators
Bochtler, M., Kolano, A., & Xu, G. (2017) · BioEssays · doi:10.1002/bies.201600178 · Cited by 170
“tase (FH) [98], and isocitrate dehydrogenase (IDH1/IDH2)”
BackgroundInfluentialCurrent Approaches and Recent Developments in the Management of Head and Neck Paragangliomas
Taïeb, D., Kaliski, A., Boedeker, C. C., Martucci, V., Fojo, T., Adler, J. R., & Pacak, K. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1026 · Cited by 170
Succinate inhibition of α-ketoglutarate-dependent enzymes in a yeast model of paraganglioma
Smith, E. H., Janknecht, R., & Maher, L. J. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm275 · Cited by 169
“Both patients carried an SDHB mutation in the iron-sulfur cluster region of the gene (I127S) and lost the second copy of SDHB in PGL tumors ( 57 ).”
BackgroundSuccinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – A review
Miettinen, M., & Lasota, J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.05.033 · Cited by 168
Hereditary leiomyomatosis and renal cell carcinoma
Schmidt, L. S., & Linehan, W. M. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s42097 · Cited by 168
“44,45 In addition, fumarate is an electrophile, and reacts spontaneously with the sulfhydryl moiety of cysteines, a reaction termed succination, 46 which is known to modify the activity of a number of proteins and can be detected by an immunohistochemical assay.”
Farrugia, F., & Charalampopoulos, A. A. (2019) · Endocrine Regulations · doi:10.2478/enr-2019-0020 · Cited by 168
“HIFs contribute to the pathogenesis of various diseases.”
BackgroundInfluentialRationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
Joshua, A. M., Ezzat, S., Asa, S. L., Evans, A. J., Broom, R. J., Freeman, M., & Knox, J. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1836 · Cited by 166
Kuiper, C., & Vissers, M. C. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00359 · Cited by 163
“HIF-1 activity can be increased by mutations in the TCA cycle enzymes succinate dehydrogenase and fumarate dehydrogenase, which cause a build-up of succinate and fumarate, respectively (37).”
BackgroundThe role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic
Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., & Giardina, B. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00314.2006 · Cited by 163
“This inhibition, in turn, may render neoplastic cells more resistant to apoptotic signals and activate a pseudohypoxic response (mediated by hypoxia-inducible factor) that enhances glycolysis (84).”
BackgroundMitochondria and Cancer: A Growing Role in Apoptosis, Cancer Cell Metabolism and Dedifferentiation
Scatena, R. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_13 · Cited by 163
“Other isoforms (IDH1 and 3) of the enzyme catalyse the same reaction; however, this reaction is unrelated to the TCA cycle and is carried out in the cytosol and uses NADP+. Pollard et al. ( 2005 ) stated that the nuclear-encoded Krebs cycle enzymes FH and SDH act as tumour suppressors, and germline mutations in these…”
BackgroundTargeting cancer metabolism – aiming at a tumour's sweet-spot
Jones, N. P., & Schulze, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 162
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 162
Bayley, J.-P., Launonen, V., & Tomlinson, I. P. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-20 · Cited by 162
Self-citationGao, R., Cheng, J., Fan, C., Shi, X., Cao, Y., Sun, B. H., Ding, H., Hu, C., Dong, F., & Yan, X. (2015) · Scientific Reports · doi:10.1038/srep18175 · Cited by 164
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
“…papillary renal carcinomas linked to FH deficiency and to paragangliomas linked to SDH defi- ciency (Gimenez-Roqueplo et al. 2001; Isaacs et al. 2005; Pollard et al. 2005; Selak et al. 2005, 2006; MacKenzie et al. 2007; Pollard et al. 2007; Sudarshan et al. 2009, 2011), although the paucity of…”
Philip, B., Ito, K., Moreno-Sanchez, R., & Ralph, S. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt209 · Cited by 161
“1 mM succinate and a lower fumarate concentration of 1 mM; or (iv) A high concentration of 10 mM fumarate which are metabolite levels found in tumours with FH mutations (57); and (v) With multiple inhibitors, using 1 mM succinate plus 1 mM fumarate plus 2 mM citrate plus 2 mM pyruvate.”
Genetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 160
Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration
Bae, J., Salamon, R. J., Brandt, E. B., Paltzer, W. G., Zhang, Z., Britt, E. C., Hacker, T. A., Fan, J., & Mahmoud, A. I. (2021) · Circulation · doi:10.1161/circulationaha.120.049952 · Cited by 160
Gardie, B., Remenieras, A., Kattygnarath, D., Bombled, J., Lefèvre, S.-H., Perrier-Trudova, V., Rustin, P., Barrois, M., Slama, A., Avril, M., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmg.2010.085068 · Cited by 160
“In renal cancers and fibroids from HLRCC patients, alpha subunits of HIF (HIF1a and 2a) are overexpressed.[32, 33] Moreover, mice with inactive Fh1 in the kidney developed proliferative renal cysts overexpressing HIF alpha subunits and hypoxia pathway”
BackgroundSelf-citationGasparre, G., Hervouet, E., de Laplanche, E., Demont, J., Pennisi, L. F., Colombel, M., Mège-Lechevallier, F., Scoazec, J.-Y., Bonora, E., Smeets, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm371 · Cited by 152
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Lehtonen, H. J. (2011) · Familial Cancer · doi:10.1007/s10689-011-9428-z · Cited by 160
“Later on, accumulation of fumarate (as well as succinate) was observed in the HLRCC tumors [76].”
BackgroundThe role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy
Tal, R., & Segars, J. H. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmt042 · Cited by 159
“Interestingly, the uterine leiomyomas in HLRCC are significantly more vascularized than sporadic leiomyomas, and show activation of components of the hypoxic pathway such as overexpression of HIF-1a and VEGF, in contrast to sporadic leiomyomas (Pollard et al., 2005a).”
BackgroundHIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 159
New and emerging renal entities: a perspective post‐ WHO 2016 classification
Trpkov, K., & Hes, O. (2018) · Histopathology · doi:10.1111/his.13727 · Cited by 158
Colson, A., Sonveaux, P., Debiève, F., & Sferruzzi-Perri, A. N. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa053 · Cited by 159
Oxidative Stress and Transcriptional Regulation in Alzheimer Disease
Shi, Q., & Gibson, G. E. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815721c3 · Cited by 157
“Enhanced H2O2 levels promote the oxidation of Fe(II) to Fe(III) and limit the availability of Fe(II) for activation of PHD and lead to stabilization of HIF.181 The TCA cycle intermediates such as pyruvate”
BackgroundAdult Leydig Cell Tumors of the Testis Caused by Germline Fumarate Hydratase Mutations
Carvajal-Carmona, L. G., Alam, N. A., Pollard, P. J., Jones, A. M., Barclay, E., Wortham, N., Pignatelli, M., Freeman, A., Pomplun, S., Ellis, I., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0183 · Cited by 145
Self-citationLin, C.-C., Cheng, T.-L., Tsai, W.-H., Tsai, H.-J., Hu, K.-H., Chang, H.-C., Yeh, C.-W., Chen, Y.-C., Liao, C.-C., & Chang, W.-T. (2012) · Scientific Reports · doi:10.1038/srep00785 · Cited by 155
Ben‐Ami, E., Barysauskas, C. M., von Mehren, M., Heinrich, M. C., Corless, C. L., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Yap, J. T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw228 · Cited by 152
“In SDH-deficient GIST, succinate dehydrogenase inactivation through mutation or methylation leads to accumulation of HIF-1α and formation of a transcription factor inducing expression of genes involved in angiogenesis (including VEGF) and glycolysis.”
ResultInfluentialIsocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 154
“Tissue analysis in HLRCC tumors revealed excessive ROS and Hif1α levels in the cytosol and nucleus [54, 55].”
BackgroundMetabolic alterations in cancer cells and therapeutic implications
Hammoudi, N., Ahmed, K. B. R., García-Prieto, C., & Huang, P. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10267 · Cited by 151
The bioenergetics of cancer: Is glycolysis the main ATP supplier in all tumor cells?
Moreno‐Sánchez, R., Rodríguez‐Enríquez, S., Saavedra, E., Marín‐Hernández, A., & Gallardo‐Pérez, J. C. (2009) · BioFactors · doi:10.1002/biof.31 · Cited by 129
Yang, Y., Valera, V. A., Padilla-Nash, H. M., Sourbier, C., Vocke, C. D., Vira, M. A., Abu-Asab, M. S., Bratslavsky, G., Tsokos, M., Merino, M. J., et al. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.08.018 · Cited by 139
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 146
Self-citationIcard, P., & Lincet, H. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.001 · Cited by 149
“cinate and fumarate as a result of mutations in succinate dehydrogenase (SDH) and/or fumarate hydratase (FH) [68–70], which act as suppressor”
BackgroundHypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Chen, S., & Sang, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25283 · Cited by 146
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 144
“…functionally characterized SDH or FH mutations result in either a complete loss or reduction in enzymatic activity (Alam et al., 2003; King et al., 2006; Pollard et al., 2005; Tomlinson et al., 2002), leading to the accumulation of their substrate metabolites, succinate, and fumarate, respectively.”
BackgroundSormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 141
“Therefore, lossof-function mutations of the tumor suppressor genes encoding the succinate dehydrogenase complex and fumarate hydratase lead to the accumulation of succinate or fumarate, resulting in HIF stabilization through inhibition of PHDs (56).”
BackgroundInfluentialThe α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 141
An Epigenetic Role of Mitochondria in Cancer
Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 142
“The accumulation of fumarate and succinate caused by mutation of enzymes inhibits α-KG-dependent enzymes, including TETs [91], thus leading to the global decreases in 5hmC and inactivation of FH and SDH and causing the loss of 5hmC [90,92,93].”
BackgroundInfluentialMitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer?
Lemarié, A., & Grimm, S. (2011) · Oncogene · doi:10.1038/onc.2011.167 · Cited by 140
“…inhibition of the HIF1a prolyl hydroxylase (PHD), which favours the glycolytic pathway and promotes tumour formation (GimenezRoqueplo et al., 2001; Pollard et al., 2005, 2006; Selak et al., 2005; Lehtonen et al., 2007; Cervera et al., 2008) and (2) the long-term generation of sublethal…”
BackgroundPollard, P. J., El-Bahrawy, M., Poulsom, R., Elia, G., Killick, P., Kelly, G., Hunt, T., Jeffery, R., Seedhar, P., Barwell, J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0920 · Cited by 139
Self-citationAlterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K.-L., & Xiong, Y. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 119
“Studies into the mechanism behind how mutations in SDH and FH trigger elevated levels of HIF-1α provided the first evidence that mutations in metabolic enzymes lead to the direct inhibition of α-KG-dependent dioxygenases [70].”
BackgroundThe genetic and metabolic signature of oncocytic transformation implicates HIF1α destabilization
Porcelli, A. M., Ghelli, A., Ceccarelli, C., Lang, M., Cenacchi, G., Capristo, M., Pennisi, L. F., Morra, I., Ciccarelli, E., Melcarne, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp566 · Cited by 121
Learning from oncocytic tumors: Why choose inefficient mitochondria?
Gasparre, G., Romeo, G., Rugolo, M., & Porcelli, A. M. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.08.006 · Cited by 125
Obre, E., & Rossignol, R. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.12.008 · Cited by 137
18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature?
Taïeb, D., Sebag, F., Barlier, A., Tessonnier, L., Palazzo, F. F., Morange, I., Niccoli-Sire, P., Fakhry, N., De Micco, C., Cammilleri, S., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060731 · Cited by 129
“18F-FDG PET IN CHROMAFFIN-DERIVED TUMORS •T ai¨eb et al. 715 ( 18 ,19).”
Joseph, N. M., Solomon, D. A., Frizzell, N., Rabban, J. T., Zaloudek, C. J., & Garg, K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000520 · Cited by 136
Richter, S., Peitzsch, M., Rapizzi, E., Lenders, J. W., Qin, N., de Cubas, A. A., Schiavi, F., Rao, J. U., Beuschlein, F., Quinkler, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2151 · Cited by 135
Multi-site control and regulation of mitochondrial energy production
Bénard, G., Bellancé, N., José, C., Melser, S., Nouette‐Gaulain, K., & Rossignol, R. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.02.030 · Cited by 138
“complex II [140,145] or in the Krebs cycle isocitrate dehydrogenase (IDH1, IDH2) [146–148] exposed a novel mechanism of pseudo-hypoxic”
BackgroundProlyl 4‐hydroxylases, master regulators of the hypoxia response
Myllyharju, J. (2013) · Acta Physiologica · doi:10.1111/apha.12096 · Cited by 134
Pharmacological targeting of the HIF hydroxylases – A new field in medicine development
Chan, M. C., Holt‐Martyn, J. P., Schofield, C. J., & Ratcliffe, P. J. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.01.001 · Cited by 135
Bayley, J., & Devilee, P. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.02.008 · Cited by 131
Tumor Biology and Prognostic Factors in Renal Cell Carcinoma
Finley, D. S., Pantuck, A. J., & Belldegrun, A. S. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s2-04 · Cited by 132
Tseng, P., Wu, W.-H., Hu, T., Chen, C., Cheng, H.-C., Li, C., Tsai, W., Tsai, H.-J., Hsieh, M.-C., Chuang, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21361-6 · Cited by 129
Sousa Fialho, M. D. L., Abd Jamil, A. H., Stannard, G. A., & Heather, L. C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.024 · Cited by 112
Siddiq, A., Aminova, L. R., & Ratan, R. R. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9268-7 · Cited by 129
“There are contradictory reports regarding the effects of other TCA cycle metabolites such as fumarate and succinate on HIF-1 activation [59,73-75].”
BackgroundMitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia
Smolková, K., Bellancé, N., Scandurra, F. M., Genot, E. M., Gnaiger, E., Plecitá‐Hlavatá, L., Ježek, P., & Rossignol, R. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9267-x · Cited by 129
“…involve HIF1α, PGC-1α, and c-myc which are the main orchestrators of the pseudo-hypoxic metabolic changes (Bratslavsky et al. 2007; King et al. 2006; Pollard et al. 2005) and the energy-dependent control of mitochondrial biogenesis (Ventura-Clapier et al. 2008) and glutaminolysis (Gao et al.…”
BackgroundProfiling metabolic networks to study cancer metabolism
Hiller, K., & Metallo, C. M. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.11.001 · Cited by 111
Ralph, S. J., Moreno-Sánchez, R., Neuzil, J., & Rodríguez-Enríquez, S. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0566-7 · Cited by 126
“Two studies found increased HIF-1 and greater succinate levels but no signs of redox stress (165,173,174).”
BackgroundPillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 126
Cancer-derived extracellular succinate: a driver of cancer metastasis
Kuo, C.-C., Wu, J.-Y., & Wu, K. K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00878-z · Cited by 125
Hypoxia in cancer cell metabolism and pH regulation
Brahimi-Horn, M. C., & Pouysségur, J. (2007) · Essays in Biochemistry · doi:10.1042/bse0430165 · Cited by 113
Autophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You Stronger
Mathew, R., & White, E. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.011015 · Cited by 123
“The TCA cycle enzymes, succinate dehydrogenase (SDH; also a member of mitochondrial respiratory chain complex II) and fumarate hydratase (FH) have important tumor suppressor roles, and LOF mutations in these genes cause aberrant accumulation in succinate and fumarate.”
BackgroundMetabolic recoding of epigenetics in cancer
Wang, Y., & Lei, Q. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0302-3 · Cited by 123
JmjC enzyme KDM2A is a regulator of rRNA transcription in response to starvation
Tanaka, Y., Okamoto, K., Teye, K., Umata, T., Yamagiwa, N., Suto, Y., Zhang, Y., & Tsuneoka, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.56 · Cited by 123
“PHD is an a-KG-dependent enzyme that catalyses a-KG to succinate during its hydroxylation reaction; in turn, the accumulated succinate inhibits PHD activity even under normoxia, which results in pseudohypoxia (Isaacs et al, 2005; Pollard et al, 2005; Selak et al, 2005).”
BackgroundLi, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., Mao, M., Bartz, S., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00282-07 · Cited by 110
A chemoproteomic portrait of the oncometabolite fumarate
Kulkarni, R. A., Bak, D. W., Wei, D., Bergholtz, S. E., Briney, C. A., Shrimp, J. H., Alpsoy, A., Thorpe, A. L., Bavari, A. E., Crooks, D. R., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0217-y · Cited by 120
“For example, mutation of fumarate hydratase (FH) in the familial cancer 6 susceptibility syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC) leads to high 7 levels of intracellular fumarate.(7-8) Fumarate has been hypothesized to promote tumorigenesis both 8 by reversibly inhibiting dioxygenases involv…”
InfluentialO'Flaherty, L., Adam, J., Heather, L. C., Zhdanov, A. V., Chung, Y.-L., Miranda, M. X., Croft, J., Olpin, S., Clarke, K., Pugh, C. W., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq305 · Cited by 109
Self-citationApplications of metabolomics in cancer research
Styczynski, M. P., & Vermeersch, K. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.113622 · Cited by 118
Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells
Wenger, R. H., & Hoogewijs, D. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00736.2009 · Cited by 117
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 117
“Ketoglutarate is metabolized to succinate, fumarate, and malate through the tricarboxylic acid cycle, which in turn is again metabolized to ketoglutarate [58].”
BackgroundInfluentialGasparre, G., Kurelac, I., Capristo, M., Iommarini, L., Ghelli, A., Ceccarelli, C., Nicoletti, G., Nanni, P., De Giovanni, C., Scotlandi, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1042 · Cited by 104
“HIF1a is considered to be one of the master regulators of the metabolic adaptation needed by cancer cells to progress to malignancy (7, 8, 32).”
Background
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.